Antidiabetic oxazolidinediones and thiazolidinediones

Details for Australian Patent Application No. 2006269503 (hide)

Owner Merck & Co., Inc.

Inventors Dropinski, James F.; Meinke, Peter T.; Shi, Guo Q.; Zhang, Yong

Agent Spruson & Ferguson

Pub. Number AU-A-2006269503

PCT Pub. Number WO2007/008501

Priority 60/697,039 06.07.05 US

Filing date 30 June 2006

Wipo publication date 18 January 2007

International Classifications

C07D 413/00 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms

A61K 31/415 (2006.01) - 1,2-Diazoles

A61K 31/42 (2006.01) - Oxazoles

A61K 31/44 (2006.01) - Non-condensed pyridines

C07D 307/44 (2006.01) Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom

C07D 401/00 (2006.01) Heterocyclic compounds containing two or more hetero rings

C07D 417/00 (2006.01) Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group

Event Publications

10 January 2008 PCT application entered the National Phase

  PCT publication WO2007/008501 Priority application(s): WO2007/008501

8 July 2010 Application Lapsed, Refused Or Withdrawn, Patent Ceased or Expired

  This application lapsed under section 142(2)(a). A direction to request examination has been given for this application. Note that applications or patents shown as lapsed or ceased may be restored at a later date.

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006269504-Inhibitors of checkpoint kinases

2006269501-Treatment of cancer patients exhibiting activation of the P-glycoprotein efflux pump mechanism